Analyzing Efficacy Data at ERS: Sustained Benefits for People Living With IPF, ILD

Nerandomilast, a novel anti-fibrotic agent with improved tolerability and a dual antifibrotic/immunomodulatory mechanism, showed sustained efficacy in the FIBRONEER trials for IPF and PPF, achieving FDA approval for IPF in October 2025.

Nerandomilast's tolerability and dual antifibrotic/immunomodulatory mechanism directly address the critical non-adherence issue with current therapies, positioning it as a potential first-line treatment for IPF and PPF despite remaining questions about very long-term efficacy and the need for biomarkers.

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating comprehensive, multidisciplinary supportive care including pulmonary rehabilitation and comorbidity management.

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted education to ensure earlier therapy and better patient outcomes.